안진희

교수
  #유방암#골연부조직육종

학력

2001 .03 ~ 2003 .02울산대학교 의학 박사
1999 .03 ~ 2001 .02울산대학교 의학 석사
1989 .03 ~ 1995 .02한양대학교 의학 학사

경력

2016 .04 ~ 현재울산대학교 의과대학 서울아산병원 종양내과 교수
2012 .03 ~ 2013 .02Harvard Medical School, Dana-Faber Cancer Institute 방문연구원
2010 .04 ~ 2016 .03울산대학교 의과대학 서울아산병원 종양내과 부교수
2005 .03 ~ 2010 .03울산대학교 의과대학 서울아산병원 종양내과 조교수
2003 .03 ~ 2005 .02서울아산병원 임상전임강사
2000 .03 ~ 2003 .02서울아산병원 전임의
1996 .03 ~ 2000 .02서울아산병원 전공의
1995 .03 ~ 1996 .02서울아산병원 인턴

논문

Gemcitabine and Docetaxel Combination for Advanced Soft Tissue Sarcoma: A Nationwide Retrospective Study.

Phase III, Randomized, Double-Blind Study Comparing the Efficacy, Safety, and Immunogenicity of SB3 (Trastuzumab Biosimilar) and Reference Trastuzumab in Patients Treated With Neoadjuvant Therapy for Human Epidermal Growth Factor Receptor 2-Positive

A Randomized Feasibility Study of (18)F-Fluoroestradiol PET to Predict Pathologic Response to Neoadjuvant Therapy in Estrogen Receptor-Rich Postmenopausal Breast Cancer.

Phase I dose-escalation study of the c-Met tyrosine kinase inhibitor SAR125844 in Asian patients with advanced solid tumors, including patients with MET-amplified gastric cancer.

Phase II, multicentre, randomised trial of eribulin plus gemcitabine versus paclitaxel plus gemcitabine as first-line chemotherapy in patients with HER2-negative metastatic breast cancer.

Quality of life on TSU-68: Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline.

A randomized feasibility study of 18F-fluoroestradiol positron emission tomography to predict pathological response to neoadjuvant systemic therapy in estrogen receptor-rich postmenopausal breast cancer.

Cytoplasmic expression of high mobility group B1 (HMGB1) is associated with tumor-infiltrating lymphocytes (TILs) in breast cancer.

Long-term outcomes of tyrosine kinase inhibitor discontinuation in patients with metastatic renal cell carcinoma.

Monogenic and polygenic determinants of sarcoma risk: an international genetic study.

Next-generation sequencing reveals somatic mutations that confer exceptional response to everolimus.

Phase II trial of neoadjuvant letrozole and lapatinib in Asian postmenopausal women with estrogen receptor (ER) and human epidermal growth factor receptor 2 (HER2)-positive breast cancer [Neo-ALL-IN]: Highlighting the TILs, ER expressional change aft

Postoperative Radiotherapy After Limb-sparing Surgery for Soft-tissue Sarcomas of the Distal Extremities.

A phase 1 study of a heterologous prime-boost vaccination involving a truncated HER2 sequence in patients with HER2-expressing breast cancer.

Circulating Plasma Biomarkers for TSU-68, an Oral Antiangiogenic Agent, in Patients with Metastatic Breast Cancer.

Clinicopathologic Significance of the Intratumoral Heterogeneity of HER2 Gene Amplification in HER2-Positive Breast Cancer Patients Treated With Adjuvant Trastuzumab

Comparison of Pathologic Response Evaluation Systems after Anthracycline with/without Taxane-Based Neoadjuvant Chemotherapy among Different Subtypes of Breast Cancers

High mobility group B1 and N1 (HMGB1 and HMGN1) are associated with tumor-infiltrating lymphocytes in HER2-positive breast cancers

Prognostic Significance of Tumor-Infiltrating Lymphocytes and the Tertiary Lymphoid Structures in HER2-Positive Breast Cancer Treated With Adjuvant Trastuzumab.

Prognostic tissue biomarker exploration for patients with metastatic renal cell carcinoma receiving vascular endothelial growth factor receptor tyrosine kinase inhibitors.

Pulmonary Metastasectomy Could Prolong Overall Survival in Select Cases of Metastatic Urinary Tract Cancer.

RandomizEd phase II trial of Sunitinib four weeks on and two weeks off versus Two weeks on and One week off in metastatic clear-cell type REnal cell carcinoma: RESTORE trial.

Randomized phase II study of paclitaxel/carboplatin intercalated with gefitinib compared to paclitaxel/carboplatin alone for chemotherapy-na?ve non-small cell lung cancer in a clinically selected population excluding patients with non-smoking adenoca

Tau and PTEN status as predictive markers for response to trastuzumab and paclitaxel in patients with HER2-positive breast cancer

Vascular endothelial growth factor receptor tyrosine kinase inhibitor (VEGFR-TKI) rechallenge for patients with metastatic renal cell carcinoma after treatment failure using both VEGFR-TKI and mTOR inhibitor.

A Randomized Phase II Trial of Capecitabine Plus Vinorelbine Followed by Docetaxel Versus Adriamycin Plus Cyclophosphamide Followed by Docetaxel as Neoadjuvant Chemotherapy for Breast Cancer

Active surveillance for metastatic or recurrent renal cell carcinoma.

Combination of docetaxel and TSU-68, an oral antiangiogenic agent, in patients with metastatic breast cancer previously treated with anthracycline: randomized phase II multicenter trial

Correlations between molecular subtypes and pathologic response patterns of breast cancers after neoadjuvant chemotherapy.

Diagnostic performance of breast-specific gamma imaging in the assessment of residual tumor after neoadjuvant chemotherapy in breast cancer patients

저서

유방암 환자를 위한 치료 안내서 5판
암에 대한 모든 것 (가림건강신서 54)

보도자료

"할라벤 허가는 곧 지방육종 치료의 발전 의미"
http://www.doctorsnews.co.kr/news/articleView.html?idxno=116258

포스팅

FcrR3A-158 polymorphism and stromal tumor-infiltrating lymphocytes as predictive markers for trastuzumab-based treatment in patients with metastatic HER2-positive breast cancer

Treatment and Prognosis of Desmoid Tumor: A Single Institutional Experience of 189 Patients

Differential Expression of Major Histocompatibility Complex I in Subtypes of Breast Cancer

Differential Expression of Major Histocompatibility Complex I in Subtypes of Breast Cancer

Improvement Activities Linked with Customer Journey Map of Breast Cancer Patients

RandomizEd phase II trial of Sunitinib four-week on and two-week off vs.Two-week On and one-week off in metastatic clear cell type REnal cell carcinoma: RESTORE trial (NCT00570882)

Activity of gemcitabine-oxaliplatin (GemOx) plus prednisolone in patients with castration-resistant prostate cancer (CRPC) for whom docetaxel-based chemotherapy failed

Vascular Endothelial Growth Factor Receptor (VEGFR) Tyrosine Kinase Inhibitor (TKI) is Active in Patients with Metastatic Renal Cell Carcinoma (mRCC) with Poor Risk Features

Comparative Efficacy of Sunitinib versus Sorafenib as First-line Treatment for Patients with Metastatic Renal Cell Carcinoma

Clinical features and outcomes of leptomeningeal metastasis in patients with breast cancer: a single center experience

Gamma Knife Surgery (GKS) Alone versus GKS Followed by Whole Brain Radiotherapy (WBRT) as the Initial Treatment of Brain Metastasis

Clinicopathologic significance of the triple negative breast cancer associated with basal phenotype : a comparison with status of androgen receptor expression

Does the primary lesion have to be regarded as a target lesion when evaluating response in metastatic renal cell carcinoma (mRCC) treated with sunitinib?

Clinical characteristics, survival and prognostic factors of advanced renal cell carcinoma with predominant sarcomatoid histology

영상자료

영상자료 내용이 없습니다.

발표자료

Hepatitis B Reactivation During Adjuvant Anthracycline Based Chemotherapy in Patients with Breast Cancer : Single Institution Experience

Prognostic Significance of Stem cell Property in Breast Carcinoma: Immunohistochemical Study for CD44s and CD24

18F-FDG PET Scan as a Predictor of Survival of the Patients Receiving Neoadjuvant Chemoradiotherapy Followed by Esophagectomy

Efficacy of gemcitabine alone and in combination with vinorelbine or capecitabine in metastatic breast cancer settings of disease progression after anthracycline and taxane therapy

Multivariate Prognostic Factor Analysis in Patients with Esophageal Cancer Treated with Preoperative Chemoradiotherapy (CRT): The Importance of Pathologic Response and Lymph Node Metastasis

Gemcitabine single or combination chemotherapy in post anthracycline and taxane salvage treatment of metastatic breast cancer: Retrospective analysis of 124 patients

Hepatitis B Reactivation During Adjuvant Anthracycline Based Chemotherapy in Patients with Breast Cancer : Single Institution Experience

Multivariate prognostic factor analysis in patients with esophageal cancer treated with preoperative chemoradiation: the importance of pathologic response and lymph node metastasis

Incidence of chemotherapy-related amenorrhea and menopause-specific quality of life after adjuvant therapy in premenopausal breast cancer patients: A prospective study

Cytokeratin Expression Profiling in the Matrix-Producing Metaplastic Carcinoma of Breast

BRCA1/2 Associated Korean Breast Cancer has more often ER/C-ERBB2 negative phenotype

Bone mineral density and the risk of breast cancer

Clinicopathologic Significance of a-Basic Crystallin in Breast Cancer

Prognostic Significance of Stem Cell Property in Breast Carcinoma: Iuumonhistochemical Study for CD44s and CD24

Predictor of locoregional recurrence to plan breast conservation therapy for breast cancer

Comparison between surgical and non-surgical treatment for tonsillar squamous cell carcinoma